Dr Louise Winteringham BSc, MSc, PhD


Dr Louise WinteringhamCoordinator, Translational Cancer Research
E: louise.winteringham@perkins.uwa.edu.au
T:  +61 8 6151 0737

Profile

Dr Louise Winteringham coordinates the Translational Cancer Research Program at The Perkins. She has an extensive background in immunology and haematology focusing on the molecular and cellular biology of cancer, in particular haematological cancers. She began her research career in the in the Department of Clinical Immunology at Royal Perth Hospital where she completed her MSc investigating the impact of non-coding regions within the Major Histocompatibility Complex. Following this, she moved to London where she spent three years at St Bartholomew's Hospital. Louise was awarded the Richard Walter Gibbon Fellowship from the Faculty of Medicine, Dentistry and Health Sciences at UWA to undertake her PhD so she returned to Perth where she joined the Leukemia Laboratory at WAIMR, headed by Professor Peter Klinken. Louise has more than twenty five years experience in cancer research including the identification of several novel genes associated with the development and progression of cancer.

Dr Winteringham was a committee member of the Australasian Society for Stem Cell Research for a number of years and is actively engaged with the Leukemia Foundation WA. She has been invited by the Leukemia Foundation to speak at several educational events and patient conferences. Louise also runs the NCRIS WA node of the Australian Phenomics Network RNAi capability. This provides WA scientists with access to state of the art technology required to carry out large scale RNAi functional screens.


Selected publications

  1. Arner E. et al. (including Winteringham LN). Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. Science (2015). [NCBI PubMed Entry]
  2. Forrest A.R.R. et al. (including Winteringham LN) A promoter level mammalian expression atlas. Nature (2014) http://dx.doi.org/ 10.1038/nature13182.[NCBI PubMed Entry]
  3. Endersby R, Majewski IJ, Winteringham LN, Beaumont JG, Samuels AL, Scaife R, Lim E, Crossley M, Klinken SP, Lalonde J. 2008. Hls5 regulates erythroid differentiation by modulating GATA-1 activity. Blood 111:1946-50. [NCBI PubMed Entry]
  4. Winteringham LN, Endersby R, Kobelke S, McCulloch RK, Williams JH, Stillitano J, Cornwall SM, Ingley E, Klinken SP. 2006. Myeloid leukemia factor 1 associates with a novel heterogeneous nuclear ribonucleoprotein U-like molecule. The Journal of Biological Chemistry 281(50):38791-800. [NCBI PubMed Entry]
  5. Winteringham LN, Kobelke S, Williams JH, Ingley E, Klinken SP. 2004. Myeloid Leukemia Factor 1 inhibits erythropoietin-induced differentiation, cell cycle exit and p27Kip1 accumulation. Oncogene 23(29):5105-9. [NCBI PubMed Entry]
  6. Lim R, Winteringham LN, Williams JH, McCulloch RK, Ingley E, Tiao JY, Lalonde JP, Tsai S, Tilbrook PA, Sun Y, Wu X, Morris SW, Klinken SP. 2002. MADM, a novel adaptor protein that mediates phosphorylation of the 14-3-3 binding site of myeloid leukemia factor 1. The Journal of Biological Chemistry 277(43):40997-1008. [NCBI PubMed Entry]
  7. Williams JH, Daly LN, Ingley E, Beaumont JG, Tilbrook PA, Lalonde JP, Stillitano JP, Klinken SP. 1999. HLS7, a hemopoietic lineage switch gene homologous to the leukemia-inducing gene MLF1. The EMBO Journal 18(20):5559-66. [NCBI PubMed Entry]
Back To Top